Biomira's President and CEO appointed board member of Biotechnology Industry Organization
EDMONTON, April 20 /CNW-PRN/ - Biomira Inc. (NASDAQ: BIOM) (TSE: BRA) today announced the election of President and CEO Alex McPherson, MD, PhD, to the Biotechnology Industry Organization (BIO) Board of Directors and the Emerging Companies Section Governing Body for the 2000-2001 term.
``I am greatly honored to be chosen to serve once again on the Board of this important organization,' commented Dr. McPherson. ``BIO plays a key role in bringing together the resources and expertise to meet critical challenges in the biotech industry.'
BIO is the leading source of biotech information for industry leaders, policy-makers, media and the general public. BIO serves as an arena where industry representatives can meet, monitor and regulate legislative activities, and discuss the latest breakthroughs in biotechnology research.
Dr. McPherson previously served one year as a Board Member of BIO during the 1999-2000 term and was a Board Member of the Emerging Companies Section both in 1998-1999 and 1999-2000.
``We are pleased to have Dr. McPherson join us once again as a member of our Board,' commented Carl Feldbaum, President of BIO. ``He is a valuable asset to our organization and we value his perspective on the industry.'
Based in Washington, D.C, BIO engages in lobbying, advocacy, communications and new business development related to the biotech industry. Established in 1993, today it includes more than 850 member companies.
Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. The commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer immunotherapy. We are The Cancer Vaccine People(TM).
This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing of clinical trials, the efficacy of products or the availability of capital. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. |
